The CONCLUDE trial, involving people with T2D switching from 1BIs to Gla-300 or the new 200 U/mL formulation of insulin degludec, documented a similar rate of overall symptomatic hypoglycemia during the 36-week maintenance period [20]. Here, INS is linked to type 2 diabetes mellitus.